Study of the Immunogenicity, Safety and Tolerability of the Convacell Vaccine.

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

155

Participants

Timeline

Start Date

July 19, 2021

Primary Completion Date

August 30, 2021

Study Completion Date

December 31, 2022

Conditions

COVID-19Immunologic FactorsCoronavirus InfectionsRespiratory Tract Infections

Interventions

BIOLOGICAL

Subunit recombinant vaccine for the prevention of coronavirus infection

solution for intramuscular injection, 0.5 ml

BIOLOGICAL

Placebo

solution for intramuscular injection, 0.5 ml

Trial Locations (3)

Medvitro, LLC, Moscow

Research Institute of Vaccines and Serums them. I.I. Mechnikov, Moscow

Eco-Safety, LLC, Saint Petersburg

All Listed Sponsors

collaborator

Crocus Medical B.V (The Netherlands)

UNKNOWN

lead

St. Petersburg Research Institute of Vaccines and Sera

OTHER_GOV

NCT05156723 - Study of the Immunogenicity, Safety and Tolerability of the Convacell Vaccine. | Biotech Hunter | Biotech Hunter